A Phase 3 interventional study of K-877 0.1 mg tablet and Fenofibrate 200 mg capsule in Hyperlipidemia, sponsored by Kowa Company, Ltd.. Completed at 33 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by Kowa Company, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.
Among the 94 studies in Hyperlipidemias with a site in China, this one is the 19th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2021, is one of 20 in phase 3, and was the 32nd registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–79
Jianyin Zhou · Sites in China
Ages 18–65
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18+
Shanghai 10th People's Hospital · Sites in China
Ages 18–60
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 12 · Phase 3 20 · Phase 4 7
First in 2005; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 155 across the 78 interventional studies, 1,151 across the 16 observational. Of the 44 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 94 have an industry lead sponsor. The 10 most frequent:
Kowa Company, Ltd. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Kowa Company, Ltd. has 5 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
10 of the studies in Hyperlipidemias with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07230730Phase 3Beijing Suncadia Pharmaceuticals Co., LtdA Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | 2027-10 |
| NCT05457582Nanjing First Hospital, Nanjing Medical UniversityPCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | 2026-12-30 |
| NCT07938099Xin LiReal-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Hyperlipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients with High TG and Low HDL-C
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects are eligible to be included in the study only if all of the following criteria apply:
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria apply:
Current or planned use of any lipid-altering medications other than the study drugs, statins, or ezetimibe during the study.
i. Subjects currently on statins or ezetimibe must be at high risk for atherosclerotic CV diseases, and the dose(s) must be stable for at least 4 weeks prior to screening
ii. For subjects currently on lipid-altering medications other than statins or ezetimibe, at least 4-week (or for subjects currently on probucol at least 8 week washout period) will be required prior to the first fasting blood sampling at Screening Visit
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
Drug: Placebo capsule · Drug: K-877 0.1 mg tablet · Drug: Placebo tablet
K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily
Drug: K-877 0.1 mg tablet · Drug: Placebo capsule
Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily
Drug: Fenofibrate 200 mg capsule · Drug: Placebo tablet
Placcebo tablet x 2 twice daily, Placebo capsule once daily
Drug: Placebo tablet · Drug: Placebo capsule
K-877 0.1 mg tablet x 2 twice daily
Also known as: Pemafibrate
Fenofibrate 200 mg capsule once daily
Placebo tablet x 2 twice daily
Also known as: Placebo tablet (matching K-877)
Placebo capsule once daily
Also known as: Placebo capsule (matching fenofibrate)
K-877 0.1 mg tablet twice daily
Also known as: Pemafibrate
Placebo tablet twice daily
Also known as: Placebo tablet (matching K-877)
Percent change in fasting TG versus placebo from baseline to Weeks 8 and 12
Time frame: From baseline to Weeks 8 and 12
Percent change in fasting TG versus fenofibrate from baseline to Weeks 8 and 12
Time frame: From baseline to Weeks 8 and 12
Percentage of patients who have achieved fasting TG <150 mg/dL at the end of the treatment period
Time frame: At Week 12
Percent change from baseline to Weeks 8 and 12 in TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)
Time frame: From baseline to Weeks 8 and 12
Change from baseline to Weeks 8 and 12 in fasting TG, TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)
Time frame: From baseline to Weeks 8 and 12
Percent change from baseline to the end of the treatment period in Apo A1 and Apo B
Time frame: From baseline to Week 12
Percent change from baseline to the end of the treatment period in TG/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, LDL-C/HDL-C, LDL-C/Apo B, and Apo B/Apo A1
Time frame: From baseline to Week 12
The incidence of adverse events and adverse drug reactions after the administration of the study drug
Time frame: Up to Week 12
Change from baseline to Week 4, 8, and 12 in clinical laboratory tests (chemistry, hematology), vital signs (BP [mmHg], PR [bpm], weight [kg], waist [cm], and BMI [kg/m^2]; each parameter is evaluated individually.), 12-lead ECGs
Time frame: From baseline to Week 4, 8, and 12
Number and percentage of patients who experience laboratory abnormalities of special interest including, but not limited to ALT, AST, ALP, CK, and, creatinine during the treatment period
Time frame: Up to Week 12
Ran from Sep 2021 to primary completion in Feb 2023, 16 months.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemafibrate